The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a critical member of systemic therapy for advanced non-small-cell lung cancer (NSCLC). Erlotinib is the first-generation EGFR-TKIs, the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line age...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian-Guo, Tian, Xu, Cheng, Long, Zhou, Quan, Liu, Yuan, Zhang, Yu, Bai, Yu-ju, Ma, Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616758/
https://www.ncbi.nlm.nih.gov/pubmed/26448029
http://dx.doi.org/10.1097/MD.0000000000001719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616758/
https://www.ncbi.nlm.nih.gov/pubmed/26448029
http://dx.doi.org/10.1097/MD.0000000000001719

Ejemplares similares